NO344992B1 - Anti-GM-CSF antistoffer og anvendelser for disse - Google Patents

Anti-GM-CSF antistoffer og anvendelser for disse

Info

Publication number
NO344992B1
NO344992B1 NO20076437A NO20076437A NO344992B1 NO 344992 B1 NO344992 B1 NO 344992B1 NO 20076437 A NO20076437 A NO 20076437A NO 20076437 A NO20076437 A NO 20076437A NO 344992 B1 NO344992 B1 NO 344992B1
Authority
NO
Norway
Prior art keywords
csf antibodies
csf
antibodies
Prior art date
Application number
NO20076437A
Other languages
English (en)
Other versions
NO20076437L (no
Inventor
Stefan Steidl
Elisabeth Thomassen-Wolf
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of NO20076437L publication Critical patent/NO20076437L/no
Publication of NO344992B1 publication Critical patent/NO344992B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
NO20076437A 2005-05-18 2007-12-13 Anti-GM-CSF antistoffer og anvendelser for disse NO344992B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68200905P 2005-05-18 2005-05-18
PCT/EP2006/004696 WO2006122797A2 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor

Publications (2)

Publication Number Publication Date
NO20076437L NO20076437L (no) 2007-12-13
NO344992B1 true NO344992B1 (no) 2020-08-17

Family

ID=37114333

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076437A NO344992B1 (no) 2005-05-18 2007-12-13 Anti-GM-CSF antistoffer og anvendelser for disse

Country Status (26)

Country Link
US (5) US7867495B2 (no)
EP (4) EP2468773A3 (no)
JP (2) JP5295759B2 (no)
KR (1) KR101308087B1 (no)
CN (2) CN103087190B (no)
AR (1) AR053608A1 (no)
AU (1) AU2006249062B2 (no)
BR (1) BRPI0610796B8 (no)
CA (1) CA2608498C (no)
DK (2) DK3620171T3 (no)
ES (2) ES2527428T3 (no)
HK (1) HK1114620A1 (no)
HR (2) HRP20220755T3 (no)
HU (1) HUE058876T2 (no)
IL (1) IL187375A (no)
LT (1) LT3620171T (no)
ME (1) ME02059B (no)
NO (1) NO344992B1 (no)
NZ (1) NZ564027A (no)
PL (2) PL3620171T3 (no)
PT (2) PT1888643E (no)
RS (2) RS53743B1 (no)
RU (1) RU2447085C2 (no)
SI (2) SI3620171T1 (no)
TW (1) TWI477512B (no)
WO (1) WO2006122797A2 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013162B1 (ru) 2005-04-18 2010-02-26 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
LT3620171T (lt) 2005-05-18 2022-06-10 Morphosys Ag Anti-gm-csf antikūnai ir jų panaudojimas
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AU2008323608A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
WO2009064399A1 (en) 2007-11-13 2009-05-22 Evec Inc. Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
DK2215121T3 (en) 2007-11-26 2016-05-02 Bayer Ip Gmbh ANTI-mesothelin ANTIBODIES AND USES THEREOF
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
DK2280732T3 (en) * 2008-04-28 2019-01-28 Humanigen Inc ANTIBODIES AGAINST GRANULOCYT MACROPHAG COLONY STIMULATING FACTOR
WO2009142738A2 (en) * 2008-05-21 2009-11-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
NZ590668A (en) * 2008-07-02 2012-12-21 Emergent Product Dev Seattle TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS
RU2011127334A (ru) * 2008-12-22 2013-01-27 Де Юниверсити Оф Мельбурн Лечение остеоартрита
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
SG175305A1 (en) * 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
EP2427495A1 (en) * 2009-05-05 2012-03-14 MorphoSys AG Treatment for multiple sclerosis
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2013026059A1 (en) * 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
US20150118237A1 (en) 2012-04-23 2015-04-30 Genefrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
EP2885639B1 (en) 2012-08-17 2019-04-10 MorphoSys AG Complex-specific antibodies and antibody fragments and their use
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
CN109999195A (zh) 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN104937099B (zh) 2012-11-09 2018-03-30 基因先端领域株式会社 用于治疗癌症的抗adam28抗体
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
JP6490419B2 (ja) * 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
JP6783983B2 (ja) 2015-03-06 2020-11-11 ジーンフロンティア株式会社 抗ヒト膜型ａｄａｍ２８抗体
WO2018050111A1 (en) * 2016-09-19 2018-03-22 I-Mab Anti-gm-csf antibodies and uses thereof
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
CA3078349A1 (en) 2017-10-02 2019-04-11 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
BR112021008688A2 (pt) 2018-11-09 2021-08-10 Kiniksa Pharmaceuticals, Ltd. tratamento para arterite de célula gigante
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
AU2020287327A1 (en) 2019-06-03 2022-03-10 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with GM-CSF antagonists
WO2021188409A1 (en) 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
JP2023546657A (ja) 2020-10-26 2023-11-07 キニクサ ファーマシューティカルズ， リミテッド Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
WO2003068920A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
WO2004046330A2 (en) 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
DK1593690T3 (da) 2004-05-05 2009-11-09 Micromet Ag Fremstilling af ScFv-antistoffragmenter
LT3620171T (lt) * 2005-05-18 2022-06-10 Morphosys Ag Anti-gm-csf antikūnai ir jų panaudojimas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
WO2003068920A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KREBS B. ET AL. "High-throughput generation and engineering of recombinant human antibodies." Journal of Immunological Methods. August 2001, Vol. 254, Nr. 1-2, side 67-84., Dated: 01.01.0001 *
RAUCHENBERGER R. ET AL. "Human Combinatorial Fab Library Yielding Specific and Functional Antibodies against the Human Fibroblast Growth Factor Receptor 3." Journal of Biological Chemistry. Oktober 2003, Vol. 278, Nr. 30, side 38194-38205., Dated: 01.01.0001 *

Also Published As

Publication number Publication date
AU2006249062A1 (en) 2006-11-23
RU2007147870A (ru) 2009-06-27
US11028165B2 (en) 2021-06-08
AU2006249062B2 (en) 2012-12-20
KR101308087B1 (ko) 2013-10-16
US20170218061A1 (en) 2017-08-03
LT3620171T (lt) 2022-06-10
CA2608498A1 (en) 2006-11-23
CN101218255A (zh) 2008-07-09
CN103087190A (zh) 2013-05-08
WO2006122797B1 (en) 2007-04-19
PT3620171T (pt) 2022-06-30
DK3620171T3 (da) 2022-06-07
RS63382B1 (sr) 2022-08-31
JP5295759B2 (ja) 2013-09-18
EP2468773A2 (en) 2012-06-27
PL3620171T3 (pl) 2022-08-08
EP1888643A2 (en) 2008-02-20
EP3620171B1 (en) 2022-04-20
CN103087190B (zh) 2016-08-03
WO2006122797A2 (en) 2006-11-23
US10377820B2 (en) 2019-08-13
HUE058876T2 (hu) 2022-09-28
JP5769744B2 (ja) 2015-08-26
IL187375A (en) 2012-06-28
EP3620171A1 (en) 2020-03-11
US7867495B2 (en) 2011-01-11
HRP20150023T1 (hr) 2015-02-27
JP2008545632A (ja) 2008-12-18
KR20080015008A (ko) 2008-02-15
US20090053213A1 (en) 2009-02-26
BRPI0610796B8 (pt) 2021-05-25
NO20076437L (no) 2007-12-13
BRPI0610796B1 (pt) 2020-01-21
DK1888643T3 (en) 2015-01-05
CA2608498C (en) 2017-04-04
ES2527428T3 (es) 2015-01-23
EP3150221A1 (en) 2017-04-05
HK1114620A1 (en) 2008-11-07
RU2447085C2 (ru) 2012-04-10
PT1888643E (pt) 2015-01-14
IL187375A0 (en) 2008-02-09
TWI477512B (zh) 2015-03-21
EP2468773A3 (en) 2012-09-19
AR053608A1 (es) 2007-05-09
TW200716674A (en) 2007-05-01
CN101218255B (zh) 2013-01-09
ME02059B (me) 2015-05-20
JP2013116912A (ja) 2013-06-13
US20200024340A1 (en) 2020-01-23
US20110045000A1 (en) 2011-02-24
WO2006122797A3 (en) 2007-02-15
PL1888643T3 (pl) 2015-04-30
BRPI0610796A2 (pt) 2010-11-09
ES2918209T3 (es) 2022-07-14
EP1888643B1 (en) 2014-10-29
HRP20220755T3 (hr) 2022-09-02
NZ564027A (en) 2011-06-30
RS53743B1 (en) 2015-06-30
SI3620171T1 (sl) 2022-09-30
US20210347879A1 (en) 2021-11-11
US9751939B2 (en) 2017-09-05
SI1888643T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
NO344992B1 (no) Anti-GM-CSF antistoffer og anvendelser for disse
CY2019041I2 (el) Τροποποιημενα αντισωματα εναντι il-23
IL272883A (en) Monoclonal antibodies and their uses
DK1994055T3 (da) Anti-5t4-antistoffer og anvendelser deraf
LTPA2016026I1 (lt) Anti-il-17 antikūnai
NO20080692L (no) SP35 antistoffer og anvendelse derav
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
NO20071430L (no) Anti-OX4OL antistoffer
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
DK2907827T3 (da) Humaniserede anti-faktor D-antistoffer og anvendelser deraf
IL191820A0 (en) Anti-ox40l antibodies and methods using same
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
IL222922A (en) Antibodies against neurophilin-1 and their use
ATE483732T1 (de) Madcam-antikörper
EP1915177A4 (en) ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES
DK2152748T3 (da) Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
EP1940466A4 (en) ANTI-ADDL MONOCLONAL ANTIBODIES AND THEIR USE
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
DK1954713T3 (da) Modificerede grønfluorescerende proteiner og fremgangsmåder til anvendelse af samme
DE602006021285D1 (de) Mikrotomklinge
DE602006017520D1 (de) Immuntestverfahren und reagens dafür
GB0507219D0 (en) Antibody and uses thereof

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MORPHOSYS AG, DE